Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction — Stella

Recruiting

Back to Early PCSK9 Inhibitor on Ventricular Remodling trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

China

Tongren Hospital, Shanghai, Shanghai, Shanghai Municipality

Shanghai tenth people's hospital, Shanghai

Key details

Phase

Post-approval study

Sponsor

Shanghai Tong Ren Hospital

Enrollment target

~20 participants

Started

April 2021

Primary completion

October 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 80 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov